CRISPR Therapeutics AG Annual Net Income (Loss) Attributable to Parent in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
CRISPR Therapeutics AG quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2014 to 2023.
  • CRISPR Therapeutics AG Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$126M, a 62.6% decline year-over-year.
  • CRISPR Therapeutics AG Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$266M, a 36.1% increase year-over-year.
  • CRISPR Therapeutics AG annual Net Income (Loss) Attributable to Parent for 2023 was -$154M, a 76.4% increase from 2022.
  • CRISPR Therapeutics AG annual Net Income (Loss) Attributable to Parent for 2022 was -$650M, a 272% decline from 2021.
  • CRISPR Therapeutics AG annual Net Income (Loss) Attributable to Parent for 2021 was $378M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$154M +$497M +76.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 -$650M -$1.03B -272% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 $378M +$727M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$349M -$416M -622% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $66.9M +$232M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$165M -$96.6M -141% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 -$68.4M -$45.2M -195% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 -$23.2M +$2.33M +9.12% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
2015 -$25.5M -$18.5M -264% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$7.01M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.